Addex Therapeutics Ltd. Sponsored ADR ADXN

Addex Therapeutics has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its collaboration with Indivior UK Limited, following Indivior’s R&D rationalization and a planned merger of its parent with Supernus Pharmaceuticals. Addex now owns the development candidate Indivior selected for substance use disorders and its own candidate for chronic cough, plus the broader GABAB PAM portfolio, enabling strategic options such as new partnerships or advancing programs independently. The returned asset augments Addex’s existing GABAB PAM program for chronic cough and broadens potential applications across substance use disorders, chronic cough, pain, overactive bladder, and neurodevelopmental or other disorders where GABAB signaling modulation is promising. GABAB PAMs enhance endogenous GABA signaling via allosteric sites, potentially offering improved tolerability versus orthosteric agonists like baclofen. Regaining full global rights expands the pipeline and strategic options, potentially boosting long-term value and partnerships.

Addex Therapeutics said it will report its 2026 half-year and second-quarter financial results on Sept. 28, 2026. CEO Tim Dyer and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review the company’s product pipeline during a 16:00 CET teleconference and webcast for investors, analysts and media (register in advance; dial-in numbers and a unique PIN will be provided). The release notes Addex’s focus on novel small-molecule allosteric modulators for neurological disorders, including lead candidate dipraglurant (mGlu5 NAM) evaluated for brain-injury recovery, and Indivior’s selection of a GABAB PAM for substance-use disorders. Addex also advances an independent GABAB PAM program for chronic cough, holds 20% equity in Neurosterix US Holdings, and has invested in Stalicla. Shares trade on SIX and NASDAQ under ticker ADXN. Upcoming half-year and Q2 results plus product-pipeline updates could moderately influence investor sentiment and near-term valuation.

Addex Therapeutics raised USD 2.8 million through its ATM agreement and extended its cash runway to the fourth quarter of 2027. Modest capital raise extends financial runway to 2027 without altering core operations or competitive positioning.

Addex Therapeutics Ltd (ADXN) highlighted strategic advances during its Q1 2026 earnings call. Earnings call details on strategic advances may moderately influence ADXN investor sentiment and near-term performance.

Addex Therapeutics reports Q1 2026 financial results and issues corporate update. Quarterly results release can move near-term stock price via updated financials and pipeline status.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) reported full year 2025 financial results and provided a corporate update. Full-year financial results and corporate updates represent major disclosures that can significantly alter investor sentiment and stock trajectory for a clinical-stage biotech.

Addex Therapeutics has entered an option and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property related to mGlu5 inhibitors aimed at brain injury recovery. The collaboration will involve evaluating Addex's dipraglurant, an mGlu5 negative allosteric modulator, for treating brain injuries. Addex will pay an undisclosed option fee to Sinntaxis, which will also assist in preclinical evaluations and clinical planning. The agreement is part of Addex's strategy to reposition dipraglurant for unmet medical needs in brain recovery, particularly for stroke and traumatic brain injury patients. The agreement represents a significant strategic move that could enhance Addex's product pipeline and market positioning in a critical therapeutic area.

Addex Therapeutics' GABAB PAM candidate demonstrated solid anti-tussive activity in a bleomycin-induced IPF-related chronic cough model. Positive preclinical efficacy data in IPF-related chronic cough model advances Addex's GABAB PAM pipeline and could significantly enhance investor sentiment and stock performance.

Addex Therapeutics' GABAB positive allosteric modulator candidate demonstrated robust anti-tussive activity in a non-human primate chronic cough model. Positive NHP data in chronic cough model advances pipeline, potentially attracting partnerships and improving investor sentiment.

Addex Therapeutics Ltd. announced the publication of preclinical data that supports the potential of mGlu7 negative allosteric modulators in transforming the treatment of anxiety and fear-related disorders. The findings suggest that these modulators could offer a new therapeutic approach, potentially improving outcomes for patients suffering from these conditions. The publication of preclinical data indicates significant advancements in treatment options, which could enhance the company's competitive position and investor sentiment.

Addex Therapeutics Ltd. has announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study for NTX-253, an M4 positive allosteric modulator, aimed at treating schizophrenia. This study marks a significant step in the development of new therapeutic options for this mental health condition. The initiation of a Phase 1 clinical study for a new treatment in schizophrenia could significantly impact Addex's future performance and market position.

Addex Therapeutics Ltd. has amended its at-the-market offering agreement with H.C. Wainwright & Co. to enhance its capital-raising capabilities. The updated agreement allows for the sale of up to $50 million of its American Depositary Shares (ADS) over a period of time, providing the company with greater financial flexibility to support its ongoing development programs. The amendment to the offering agreement may provide necessary funding for development programs, influencing financial performance moderately.

Addex Therapeutics Ltd. reported its Q3 2025 earnings, highlighting strategic advances in its pipeline and ongoing projects. The company emphasized progress in its drug development initiatives and collaborations, aiming to enhance its market position. Financial results showed a commitment to innovation and growth, with management outlining future plans to leverage recent advancements for sustained performance. Significant strategic moves and advancements in drug development are expected to impact future performance and investor sentiment.

Addex Therapeutics Ltd. reported its financial results for the third quarter of 2025, highlighting key metrics and providing a corporate update. The company continues to focus on its pipeline and strategic initiatives aimed at advancing its therapeutic programs. Financial performance showed trends that may influence future operations and investor sentiment. Financial results and corporate updates indicate moderate influence on future performance and market positioning.

Addex Therapeutics Ltd. reported significant advancements during its Q2 2025 earnings call, highlighting strategic initiatives aimed at enhancing its product pipeline and market position. The company discussed ongoing clinical trials and collaborations that are expected to drive future growth. Financial results showed a positive trend, with increased revenue and reduced expenses, reflecting effective cost management. Management emphasized their commitment to innovation and addressing unmet medical needs, positioning Addex for potential long-term success in the biopharmaceutical sector. Strategic initiatives and positive financial trends are likely to significantly influence the company's future performance and market sentiment.

Addex Therapeutics Ltd. reported its financial results for the first half of 2025, highlighting key metrics and providing a corporate update. The company continues to focus on its pipeline and strategic initiatives aimed at advancing its therapeutic programs. Financial performance showed trends that may influence future operations and market positioning. Financial results and corporate updates indicate moderate influence on future performance and market sentiment.

Addex Therapeutics Ltd. has appointed Bank of New York Mellon as its Depositary Bank. This partnership aims to enhance the company's American Depositary Receipt (ADR) program, facilitating better access for U.S. investors and improving liquidity. The move is expected to streamline operations and support the company's growth strategy in the U.S. market. The appointment of a Depositary Bank may moderately influence investor access and liquidity, impacting market sentiment and operations.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) is highlighted as one of three promising penny stocks in the European market. The company is noted for its innovative approaches in drug development, particularly in the treatment of neurological disorders. Investors are encouraged to consider the potential upside as the company navigates its growth trajectory amidst a competitive landscape. The company's innovative drug development efforts may moderately influence its financial performance and market positioning.

Addex Therapeutics has led a CHF 2 million investment in Stalicla, a company focused on precision medicine for neuropsychiatric disorders. The funding will support Stalicla's autism-focused drug candidates and general corporate activities. Addex CEO Tim Dyer joins Stalicla's Board as Chairman. This investment aligns with Addex's strategy to advance precision therapeutics in CNS disorders, particularly as Stalicla prepares for Phase 2 trials for its autism candidates and progresses its STP7 program for cocaine use disorders. The investment in Stalicla represents a significant strategic move that could enhance Addex's position in the neuropsychiatric market and influence future financial performance.

Stalicla SA has secured CHF 2 million in financing led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders. This funding will support operations and program development as Stalicla prepares for a Series C financing and partnerships. The company is progressing its STP7 program, a Phase 3 ready mGluR5 negative allosteric modulator, with funding from the NIH-NIDA. Tim Dyer has been appointed as Chairman of Stalicla's Board of Directors. Stalicla has raised over $50 million in equity and more than $30 million in non-dilutive funding to date. The financing and strategic partnership with Addex are likely to significantly enhance Stalicla's capabilities and market position in neurodevelopmental disorder treatments.

Addex Therapeutics Ltd. reported its Q1 2025 financial results, highlighting key metrics and providing a corporate update. The company discussed its ongoing projects and strategic initiatives aimed at advancing its pipeline and enhancing shareholder value. Financial performance showed trends that may influence future operations and market positioning. Financial results and corporate updates indicate moderate influence on future performance and market sentiment.

Addex Therapeutics announced robust anti-tussive activity of its GABAB positive allosteric modulator (PAM) in preclinical models of chronic cough, showing superior efficacy and tolerability compared to reference drugs. Data will be presented at the American Cough Conference on June 7, 2025. The company plans to advance the candidate into IND enabling studies, aiming to provide a once-daily treatment for refractory chronic cough. GABAB PAM offers advantages over baclofen, including higher selectivity and better tolerability. The advancement of the GABAB PAM candidate into IND enabling studies represents a significant strategic move that could alter the company's trajectory and investor sentiment.

Addex Therapeutics announced that it will present positive preclinical data on its GABAB positive allosteric modulator (PAM) for chronic cough at the 10th American Cough Conference on June 7, 2025. The presentation will highlight antitussive efficacy and a favorable therapeutic margin observed in guinea pig models. The lead drug candidate is set to begin IND enabling studies. GABAB receptors play a crucial role in cough regulation, and targeting them with allosteric modulators may offer advantages over traditional treatments like baclofen, which has limitations due to side effects and tolerance issues. The presentation of positive data and the advancement of the GABAB PAM program could significantly impact Addex's future product offerings and market position.

Addex Therapeutics announced that its partner Indivior has successfully advanced the GABAB positive allosteric modulator (PAM) program through IND enabling studies, marking the final preclinical stage before clinical trials. CEO Tim Dyer highlighted the progress and quality of compounds developed through their collaboration. Addex is also advancing its own GABAB PAM program for chronic cough, with potential milestone payments of up to USD 330 million from Indivior. The GABAB PAMs are expected to offer efficacy with fewer side effects compared to traditional agonists like baclofen. Advancements in the GABAB PAM program and potential milestone payments indicate significant strategic progress for Addex.

Addex Therapeutics Ltd. reported its financial results for the full year 2024, highlighting key metrics and developments in its corporate strategy. The company provided updates on its ongoing projects and future plans, emphasizing its commitment to advancing its therapeutic pipeline. Financial performance showed trends that may influence investor sentiment and operational focus moving forward. The financial results and corporate updates indicate moderate influence on the company's future performance and market positioning.

Addex Therapeutics Ltd. has regained rights to its Phase 2 mGlu2 PAM asset, ADX71149, from Janssen Pharmaceuticals. This asset is being developed for the treatment of various neurological disorders, including Parkinson's disease and schizophrenia. The transfer of rights is expected to enhance Addex's strategic focus and development capabilities in its pipeline. The company plans to advance ADX71149 into further clinical trials, aiming to leverage its potential in addressing unmet medical needs. Regaining rights to a significant asset like ADX71149 is likely to have a substantial impact on Addex's strategic direction and market positioning.

Adma Biologics (ADMA) has significantly outperformed its peers in the Medical sector this year, with a year-to-date return of 382.7%, compared to the sector's average gain of 1.5%. The company's Zacks Rank is #2 (Buy), and its earnings estimates have improved by 5.4%. Addex Therapeutics Ltd. Sponsored ADR (ADXN) has also shown strong performance, returning 45.1% year-to-date, with a Zacks Rank of #2 and a 236.1% increase in its EPS estimate. While ADMA belongs to the Medical - Biomedical and Genetics industry, ADXN is part of the Medical - Drugs industry, which has seen a decline of 3.9% this year. Both stocks are recommended for investors interested in Medical stocks. Both companies are showing strong performance and positive earnings outlooks, but the overall market dynamics remain mixed.

Addex reports third quarter 2024 financial results and provides corporate update. The financial results and corporate update may moderately influence key areas such as financial performance and competitive positioning.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) has shown strong year-to-date performance, returning approximately 74.4%, significantly outperforming the average 4.7% return of the Medical sector. The stock holds a Zacks Rank of #2 (Buy), with a 244.1% increase in the consensus earnings estimate over the past 90 days. In contrast, the Medical - Drugs industry, which includes ADXN, has seen a decline of about 0.5% this year. Another outperforming stock in the Medical sector is Adma Biologics (ADMA), which has returned 400.4% year-to-date. Investors are encouraged to monitor both ADXN and ADMA for continued strong performance. The significant increase in earnings estimates and strong year-to-date performance indicate a likely positive shift in investor sentiment and market positioning for ADXN.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive earnings outlook. The Zacks Consensus Estimate for the fiscal year ending December 2024 is projected at $0.49 per share, reflecting a 102.6% increase from the previous year. Over the past three months, estimates have risen by 104.2%. The Zacks rating system, which ranks stocks based on earnings estimate revisions, positions Addex in the top 20% of covered stocks, suggesting potential for near-term price increases. The upgrade and significant increase in earnings estimates indicate a likely positive shift in investor sentiment and stock performance.